SOLIGENIX, INC. SNGX
Pharmaceutical Preparations · CIK 0000812796 · Fiscal year ends 1231
Revenue
$119.37K
Fiscal year ended 2024-12-31Operating income
-$9.44M
Fiscal year ended 2024-12-31Free cash flow
—Unavailable
Fiscal year ended 2024-12-31Valuation, from the filing
| Public float | $4.59M | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|
| Float per share | $0.45 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
|---|
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.
How this compares in its industry
Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
SOLIGENIX, INC. (SNGX) reported revenue of $119.37K and net income of -$8.27M for the fiscal year ended 2024-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from SOLIGENIX, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
Balance
Cash flow
Derived
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SNGX in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.